Algeria and Niger Explore Pharmaceutical Cooperation to Boost Trade and Industry Ties
Image: El Mawkie
Takeaway
The Algerian-Nigerien pharmaceutical cooperation presents an opportunity for investors looking to capitalize on the growing healthcare market in West Africa. Pharmaceutical companies should monitor regulatory developments and explore potential partnerships with local manufacturers to gain a foothold in the region. Increased trade flows between Algeria and Niger may also impact shipping and logistics companies operating in the region.
Algeria's Minister of Pharmaceutical Industry, Dr. Wassim Kouidri, met with Niger's Minister of Health, Mr. Garba Hakimi, to discuss ways to enhance bilateral cooperation in the pharmaceutical industry. The meeting took place in Niamey, Niger, on March 24, 2026, on the sidelines of the second session of the Algerian-Nigerien Joint Grand Commission for Cooperation. The session was overseen by Algerian Prime Minister, Mr. Seifi Gherrib, and his Nigerien counterpart during an official visit. Minister of Industry, Mr. Yahya Bachir, along with the Minister of Trade and Export Promotion, Mr. Kamal Rezik, also attended a meeting at the Ministry of Trade and Industry in Niamey to discuss ways to strengthen and develop cooperation in trade and industrial fields.
This collaboration signifies Algeria's broader strategy to diversify its economy and strengthen ties with neighboring African countries. Algeria has been actively seeking to expand its influence in the region through various economic partnerships. In 2025, Algeria inaugurated a 950-km railway to Gara Djebilet to facilitate iron ore shipments, demonstrating its commitment to infrastructure development and resource exploitation. Such initiatives align with Algeria's ambition to become a key player in regional trade and industry, reducing its reliance on hydrocarbon exports.
The pharmaceutical sector in Algeria has been undergoing significant development, with the government encouraging local production and attracting foreign investment. Increased cooperation with Niger could lead to joint ventures in pharmaceutical manufacturing, technology transfer, and the harmonization of regulatory standards. This partnership could potentially create opportunities for Algerian pharmaceutical companies to expand their market reach into Niger and other West African countries. Comparable deals in the region have seen investments ranging from $5 million to $20 million, depending on the scale and scope of the projects.
Increased pharmaceutical cooperation between Algeria and Niger is expected to benefit both countries by enhancing access to essential medicines and promoting economic growth. Algerian pharmaceutical companies, such as Saidal Group, could see increased export opportunities, while Niger would benefit from a more reliable supply of pharmaceuticals. This collaboration could also impact regional supply chains by reducing dependence on imports from outside the continent. European and Asian pharmaceutical exporters may face increased competition in the Nigerien market.
Looking ahead, the Algerian and Nigerien governments are expected to establish specific working groups to identify and implement concrete projects in the pharmaceutical sector. Key areas to watch include the establishment of joint manufacturing facilities, the development of training programs for pharmaceutical professionals, and the harmonization of drug registration procedures. Any delays in these initiatives or political instability in either country could pose risks to the successful implementation of the cooperation agreement.